GeneGo, Inc., a St. Joseph, MI-based systems biology tools company, has been awarded a $336K Phase I SBIR grant from the National Institute of General Medical Sciences.
The grant has been awarded to create a novel type of predictive signatures for drug resistance. Under this project GeneGo will develop “regulation signatures” which should overcome many shortcomings of existing methods of molecular diagnostics.
For this work GeneGo will utilize its extensive, manually-curated database of signaling interactions and recently developed algorithms for identifying key proteins in signaling networks.
The work will be performed in collaboration with the Van Andel Institute for Translational Medicine.
FinSMEs
12/01/2010